Wednesday, May 31, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Defense + Military

Developing Shark Antibodies for Warfighter Protection

by Global Biodefense Staff
October 24, 2016
Shark Antibody Research

Shark Antibody ResearchIn new research funded by the Defense Threat Reduction Agency, Naval Research Laboratory (NRL) scientists are developing shark antibodies for use as chemical and biological threat detection and treatment tools.

Current detection and treatment applications use mammal antibodies. However, shark antibodies are smaller and more thermally stable when heated, allowing for greater structure and binding retention qualities. These properties allow for more consistent product development of therapeutic and diagnostic tools and reduce the logistical cost of shipping and storing since refrigeration would no longer be required.

Other advantages include the ability of single-domain antibodies to be rationally-selected, tailored to specific applications and easier to mass-produce by standard recombinant technology.

The NRL researchers recently published results in the journal PLOS ONE, demonstrating their molecular engineering of shark-derived antibodies to increase thermal stability.

“Shark derived sdAb offer an important alternative to both conventional antibodies and camelid sdAb for therapeutic, detection, and biotechnology applications,” state the authors. “Through CDR grafting, coupled with site directed mutagenesis, we were successful in finding a variant of shark096 that has an increased melting temperature while maintaining high affinity.”

Read more: Importance of Hypervariable Region 2 for Stability and Affinity of a Shark Single-Domain Antibody Specific for Ebola Virus Nucleoprotein.

Article adapted from original by Defense Threat Reduction Agency’s Chemical and Biological Technologies Department.

Related Posts

Vials of finished vaccines
Funding News

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics
Industry News

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023
Medical Countermeasures

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Load More

Latest News

Vials of finished vaccines

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

April 26, 2023
Biodefense Headlines – 25 April 2023

Biodefense Headlines – 25 April 2023

April 25, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2023 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2023 Stemar Media Group LLC